Home
PharmAbcine

PharmAbcine Market Share Analysis for May 2026

PharmAbcine

Industry: N/A

Domainpharmabcine.com

Year Founded2008

Employees51 - 200

Annual Revenue$10M - $15M

PharmAbcine

PharmAbcine (including company regionals)

pharmabcine.com

See more website traffic and engagement information

PharmAbcine Revenue up to May 2026 is 10M - 15M

revenue generated by PharmAbcine top domains

PharmAbcine top domains revenue over 3 years

Revenue for PharmAbcine top domains

pharmabcine.com10M - 15M

See more with Sales Intelligence

Total visits to PharmAbcine's top domains

Understand PharmAbcine market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

pharmabcine.com4.3K

See more with Sales Intelligence

Avg. visit duration in PharmAbcine's top domains

Analyze PharmAbcine engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

pharmabcine.com00:01:14

See more with Sales Intelligence

Avg. pageviews on PharmAbcine's top domains

See how PharmAbcine keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

pharmabcine.com1.55

See more with Sales Intelligence

PharmAbcine top competitors by domain

Looks like there’s not enough data here

No Data to Display

Top technologies used by PharmAbcine

These are the website technologies, by industry, used by PharmAbcine top domains

Payment & Currencies (4)

PayPal

Advertising (3)

DoubleClick

eCommerce (3)

Swap

Social (3)

Facebook Social Plugins

More Technologies

10

See all

News & Signals from PharmAbcine

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsPharmAbcine Inc. launched Tie2-activating antibody program, PMC-403, in treating Idiopathic Systemic Capillary Leak Syndrome on Nov 22nd '23.PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next-generation antibody therapeutics, announces the publication of preclinical research in Science Advances, highlighting the potential of its Tie2-activating antibody program, PMC-403, in treating Idiopathic Systemic Capillary Leak Syndrome (ISCLS).

NewsPharmAbcine Inc. launches PMC-403.PharmAbcine already announced that PMC-403, even with its unique mechanism, reduced the size of retinal leakages in both mouse and monkey models comparable to a control group treated with aflibercept, the best-selling anti-VEGF drug in the current market.

NewsPharmAbcine Inc. launched GLP toxicology study of PMC-403 on Apr 26th '22.PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next-generation antibody therapeutics, announced today the positive results from the GLP toxicology study of PMC-403, the Company's novel TIE2-activating antibody.